The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
about
Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsyLong-term neuropathological and behavioral impairments after exposure to nerve agentsLY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.The recovery of acetylcholinesterase activity and the progression of neuropathological and pathophysiological alterations in the rat basolateral amygdala after soman-induced status epilepticus: relation to anxiety-like behavior.Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors.Reduced GABAergic inhibition in the basolateral amygdala and the development of anxiety-like behaviors after mild traumatic brain injury.Pathophysiological mechanisms underlying increased anxiety after soman exposure: reduced GABAergic inhibition in the basolateral amygdala.Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonistsEfficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administrationAdvances in toxicology and medical treatment of chemical warfare nerve agentsThe basolateral amygdala γ-aminobutyric acidergic system in health and disease.Temporal course of changes in gene expression suggests a cytokine-related mechanism for long-term hippocampal alteration after controlled cortical impact.New AMPA antagonists in epilepsy.Treatment of status epilepticus with ketamine, are we there yet?Neurosteroids for the potential protection of humans against organophosphate toxicity.Recent advances in the treatment of organophosphorous poisonings.Alpha-Linolenic Acid Treatment Reduces the Contusion and Prevents the Development of Anxiety-Like Behavior Induced by a Mild Traumatic Brain Injury in Rats.Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala.Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.
P2860
Q26859135-9B29A977-B952-4BF2-8738-A1B94C0BBAF2Q30354960-B5456F93-2F59-45EC-9732-AF4B89FE86F8Q30392504-E9853BF7-0469-47D0-9470-C53A16A5997AQ30399944-42CB423E-381D-4BCE-A692-3A0905706CDBQ30410510-CA895FD5-40C9-409A-A1DC-0C3BFB055448Q30448913-D66F6500-3E65-4CB6-A710-910B27472E70Q33927727-04A7DCEE-37F9-42BB-AC64-2B3223E79E3FQ34243946-30D4419F-92D7-45CF-AEA2-8124BEC8AFD3Q35564288-9A12C1F7-9977-4D59-A3A4-29C751C53B62Q35985022-1E3F14CA-F388-49AB-8E64-8359387BDB66Q36497607-BC8AB8C2-F144-4595-91DF-69D57658EC0AQ36565002-BD7BD311-DE19-44FC-91F2-5E1130D50104Q36813950-EBB26B35-6B94-430C-A3AD-B1D3C0E404ADQ37653743-7CE5FE7E-587A-4DC3-B7B5-6326F2548E39Q38025721-711F9C76-C588-4DDD-A716-2D587E3DB323Q38100382-2EF2087A-07C6-4CA5-9FF7-00F0B6605CA8Q38906587-6A5E543E-55B9-4564-9401-589986717F65Q42027845-37B590A4-A357-45D0-81D4-0CB925B4371FQ48138442-799B5A73-026E-49E2-ACBF-53C0854EA478Q48166589-0E67EB26-F21B-4066-AC0A-65A64E7B5200Q48448168-887D6A2F-2B37-45BE-9CA2-126BC0CC7A1CQ51749309-8FA1A795-DF94-4282-B915-6B4FCEEBDF55
P2860
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@ast
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@en
The GluK1
@nl
type
label
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@ast
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@en
The GluK1
@nl
prefLabel
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@ast
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@en
The GluK1
@nl
P2093
P2860
P356
P1476
The GluK1 (GluR5) Kainate/{alp ...... d seizures and neuropathology.
@en
P2093
Adriana P Souza
Felicia Qashu
James P Apland
Maria F M Braga
Taiza H Figueiredo
Vassiliki Aroniadou-Anderjaska
P2860
P304
P356
10.1124/JPET.110.171835
P407
P577
2010-10-20T00:00:00Z